tetano
Editor, Senior Moderator
Infection
. 2022 Apr 28.
doi: 10.1007/s15010-022-01829-4. Online ahead of print.
Treatment of COVID-19 with monoclonal antibodies casirivimab and imdevimab in pregnancy
Rebecca Folkman[SUP] 1 [/SUP], Ola Blennow[SUP] 2 [/SUP], Tuulikki Tovatt[SUP] 2 [/SUP], Karin Pettersson[SUP] 3 [/SUP], Piotr Nowak[SUP] 2 [/SUP]
Affiliations
Abstract
Propose: Pregnancy is a risk factor for severe COVID-19. Treatment with monoclonal antibodies has been shown to decrease the risk of progression to severe COVID-19, but there are few reports on treating pregnant women. Here, we describe the clinical outcome of seven hospitalized pregnant women treated with the casirivimab-imdevimab.
Methods/results: Seven unvaccinated pregnant patients hospitalized due to COVID-19 met the monoclonal antibodies treatment criteria applied at our center. After consultations with obstetricians, the decisions to administer casirivimab-imdevimab to halt the progression of COVID-19 were made by two senior infectious diseases specialists. No patient experienced an adverse drug reaction, and only one patient progressed to severe disease. Two patients had a cesarian section performed during hospitalization, both with delivery of healthy babies. Three patients gave birth to healthy babies at a later time point, while two pregnancies are ongoing.
Conclusion: The hospitalized pregnant patients who received monoclonal antibodies due to COVID-19 had favorable outcomes, but further research is recommended to fully assess safety and efficacy of monoclonal antibody treatment in pregnancy.
Keywords: COVID-19; Coronavirus disease; Monoclonal antibodies; Pregnancy.
. 2022 Apr 28.
doi: 10.1007/s15010-022-01829-4. Online ahead of print.
Treatment of COVID-19 with monoclonal antibodies casirivimab and imdevimab in pregnancy
Rebecca Folkman[SUP] 1 [/SUP], Ola Blennow[SUP] 2 [/SUP], Tuulikki Tovatt[SUP] 2 [/SUP], Karin Pettersson[SUP] 3 [/SUP], Piotr Nowak[SUP] 2 [/SUP]
Affiliations
- PMID: 35482208
- DOI: 10.1007/s15010-022-01829-4
Abstract
Propose: Pregnancy is a risk factor for severe COVID-19. Treatment with monoclonal antibodies has been shown to decrease the risk of progression to severe COVID-19, but there are few reports on treating pregnant women. Here, we describe the clinical outcome of seven hospitalized pregnant women treated with the casirivimab-imdevimab.
Methods/results: Seven unvaccinated pregnant patients hospitalized due to COVID-19 met the monoclonal antibodies treatment criteria applied at our center. After consultations with obstetricians, the decisions to administer casirivimab-imdevimab to halt the progression of COVID-19 were made by two senior infectious diseases specialists. No patient experienced an adverse drug reaction, and only one patient progressed to severe disease. Two patients had a cesarian section performed during hospitalization, both with delivery of healthy babies. Three patients gave birth to healthy babies at a later time point, while two pregnancies are ongoing.
Conclusion: The hospitalized pregnant patients who received monoclonal antibodies due to COVID-19 had favorable outcomes, but further research is recommended to fully assess safety and efficacy of monoclonal antibody treatment in pregnancy.
Keywords: COVID-19; Coronavirus disease; Monoclonal antibodies; Pregnancy.